BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Nucleai announces partnership with Protean BioDiagnostics

May 8, 2019 | News

Nucleai and Protean BioDiagnostics are launching a co-branded campaign, Protean QA Service Enhancement powered by Nucleai



Nucleai, an Israel based precision medicine AI company in the pathology domain, announced its partnership with Protean BioDiagnostics, a Tampa-based biotech company commercializing advanced cancer diagnostic technology.

Nucleai and Protean BioDiagnostics are launching a co-branded campaign, Protean QA Service Enhancement powered by Nucleai, that will pair Nucleai's unique AI services with Protean BioDiagnostic laboratories' advanced diagnostic tools. This optimal quality assurance service enhancement will be deployed in labs, hospitals, and urology centers across the US.

Research shows that by 2030 the number of active pathologists in the US may drop by 30 percent compared to 2010 levels, and coupled with an increasing demand for biopsies, the pathology field is ripe for disruption. Protean BioDiagnostics will now have access to the most advanced AI technology on the market, backed by over 20 million slides and a team that boasts over 100 years of cumulative experience in AI, machine learning and machine vision.

Avi Veidman, CEO of Nucleai said, "We are thrilled to partner with Protean BioDiagnostics, a company who shares our mission: to use operational AI to improve the existing standard of care for cancer patients. Their strong network is a great springboard for Nucleai and will open new opportunities for mutual development of precision medicine solutions including prediction and prognosis tools."

Dr. Anthony Magliocco MD, Founder and President of Protean BioDiagnostics said, "Our mission at Protean BioDiagnostics is to offer the most advanced and personalized oncology technology to help cancer patients and their doctors in the most effective ways possible. We are very excited to collaborate with Nucleai to combine our molecular capabilities with their advanced image analysis solution to develop leading solutions in the precision medicine area."

Protean BioDiagnostics' expertise on the molecular aspects of precision medicine will help Nucleai effectively develop and scale a precision medicine solution which will be added to the company's existing technology platforms. Having proven to increase efficiency and reduce potential missed diagnoses with a 97% rate of accuracy, Nucleai's partnership with Protean BioDiagnostics will enable pathologists across the US to improve diagnoses and alleviate the biopsy bottleneck by seamlessly

integrating into pathologists' workflow.